NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Biosplice Therapeutics

Biosplice Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://biosplice.com/default.aspx

Last Round

VC Round

Apr 15, 2021

Est. Valuation

$12.44B

Total Funding Raised

$878M

Company Overview

Biosplice Therapeutics is a biotechnology company that develops tissue-level therapeutic drugs for osteoarthritis, oncology, and other degenerative conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule therapeuticsosteoarthritis treatmentalternative splicingdrug discoverybiotechkinase inhibitorclinical trialsWnt pathwaycardiometabolic diseaseoncologydrug pipelineDYRK1A inhibitorpharma R&Ddrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Biosplice Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Biosplice Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Biosplice Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 15, 2021
Series A ExtensionAug 6, 2018
Series AApr 13, 2016

Key People

Founding team and executive leadership

Cevdet Samikoglu

Chief Executive Officer

Executive Team

Erich Horsley

Chief Executive Officer

Executive Team

Phil Wilson

Chief Financial Officer

Executive Team

Biosplice Therapeutics Investors

Notable investors and investment history

Biosplice Therapeutics investors
InvestorRounds
SymBiosis Capital ManagementVC Round
Polar Light VenturesSeries A Extension
Eventide FundsVC Round
Ingka InvestmentsSeries A
aMoonVC Round
Starling GroupSeries A Extension
Vickers Venture PartnersEarly Funding, Series A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2021

    $120M round with participation from Eventide Funds and Verition Fund Management.

Biosplice Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Biosplice Therapeutics Filings

SEC and related filings with document metadata.

Appears On

Curated lists and screens where this company is featured.

Frequently Asked Questions

Common questions about Biosplice Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range30
Year Founded2008
Last FundingApr 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.